Vincent Ippolito
MD & Executive Chairman
Good evening, everyone, joining us from North America, and a pleasant good morning to everyone joining from Australia. I’m Vince Ippolito, Executive Chairman of the Board of Botanix Pharmaceuticals Limited, and we’re pleased to present the Botanix quarterly activity report and 4C quarterly cash flow report for the period ending 31 March 2026.
And the company has come a long way since our highly successful commercial launch of Sofdra, and we’re pleased with the progress that we’ve made and believe that we’re well positioned for future growth, as you’re going to see from today’s presentation. And at the end of the presentation, we’ll have time for a few questions from the audience. So please type them into the Q&A section of the webinar here.
Now we have close to 300 people that have preregistered and joined us here for today. So we’re going to most likely be consolidating like questions when we ask them. And so hopefully, we’ll be able to hit your questions and the broad-based ones that you have from today’s presentation.
On the screen, I’m joined by our Chief Executive Officer, Dr. Howie McKibbon; and our U.S. Chief Financial Officer, Chris Lesovitz, who will take you through today’s presentation.
And with that, I’m going to turn the presentation over to Howie.
Howie McKibbon
Chief Executive Officer
Yes. Thank you, Vince, and thank you all for joining today. So for the many new investors that we have on the call, we’ll give a brief corporate overview, and then we’ll get right into results and outline
